GlassScriptPhysician profile
Allie M Williams
NPI 1801263140
$1,627.29
in general payments reported to CMS, 2019-2025
24 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $125 · 2023: $366 · 2024: $279 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $399.28 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Tris Pharma INC | $187.37 | 2021-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $137.26 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $134.05 | 2021-2024 | Jornay Pm |
| Corium, LLC | $104.53 | 2022-2023 | Azstarys |
| Sanofi Pasteur INC. | $101.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $95.72 | 2022-2025 | Bexsero |
| Pfizer INC. | $77.83 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $46.63 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $44.28 | 2023 | Flumist Quadrivalent |
| Alk-Abello, INC | $41.25 | 2024 | Odactra, Grastek, Ragwitek |
| Seqirus USA INC | $34.16 | 2025 | Flucelvax |
| Neos Therapeutics, LP | $33.14 | 2021 | |
| Sobi, INC | $29.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.78 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18.90 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.52 | 2023 | |
| Genzyme Corporation | $17.64 | 2021 | |
| Neurelis, INC. | $17.45 | 2023 | Valtoco |
| Exeltis, USA INC. | $15.44 | 2025 | Slynd |
| Noven Therapeutics, LLC | $13.78 | 2025 | Xelstrym |
| Hologic Sales and Service, LLC | $13.59 | 2024 | Aptima |
| Biomarin Pharmaceutical INC. | $13.52 | 2024 | Voxzogo 1.2mg |
| Teva Pharmaceuticals USA, INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allie Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.